Barrett’s esophagus in Japanese patients: its prevalence, form, and elongation
- 203 Downloads
Barrett’s esophagus is a well-known acquired condition resulting from gastroesophageal reflux disease (GERD). However, it is still unknown whether Barrett’s esophagus develops gradually over time in patients with GERD. To address this issue, we investigated the change in the prevalence and length of short-segment Barrett’s esophagus (SSBE) over time.
From January 2005 to March 2007, we enrolled 5338 patients who received upper gastrointestinal endoscopy. Prevalence and length of endoscopically identified SSBE were evaluated within groups divided on the basis of 10-year age intervals. The factors possibly influencing SSBE length such as symptoms, antacid use, and endoscopic findings were also evaluated. Additionally, the length change in 236 patients with histologically confirmed Barrett’s esophagus was evaluated over a 2-year follow-up.
Of the 5338 enrolled patients, 1997 had SSBE. The prevalence of endoscopically identified SSBE was significantly higher and its length was significantly longer in elderly patients. Multiple regression analysis showed that age, presence of reflux esophagitis, reflux symptoms, and hiatal hernia were positively correlated with SSBE length. Analysis of the 2-year follow-up study of histologically confirmed SSBE revealed significant extension of Barrett’s length in 28.0% of 236 patients. Presence of reflux symptoms and hiatal hernia were identified as positive predictors and proton pump inhibitor administration as a negative predictor of SSBE elongation.
Positive predictors for the extension of SSBE were presence of hiatal hernia and reflux symptoms, but not age.
Key wordsBarrett’s esophagus prevalence elongation
Unable to display preview. Download preview PDF.
- 27.Amano Y, Kushiyama Y, Ishihara S, et al. Barrett’s esophagus with predominant intestinal metaplasia correlates with superficial COX-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by NSAIDs usage. Aliment Pharmacol Ther 2004;20:793–802.PubMedCrossRefGoogle Scholar
- 37.Amano Y, Chinuki D, Yuki T, Takahashi Y, Ishimura N, Kazumori H, et al. Efficacy of proton pump inhibitors for cellular proliferation and apoptosis in Barrett’s oesophagus with different mucin phenotypes. Aliment Pharmacol Ther 2006;24Suppl 4:41–48.Google Scholar
- 50.Amano Y, Kinoshita Y. Barrett’s esophagus: perspectives on its diagnosis and management in Asian populations. Gastroenterol Hepatol 2008;4:45–53.Google Scholar